Brief: Sedana Medical Receives FDA Approval For Early Access Program In U.S.
23/04/2025 07:06
April 23 (Reuters) - Sedana Medical AB (publ) SEDANA.ST: SEDANA MEDICAL RECEIVES FDA APPROVAL FOR EARLY ACCESS PROGRAM IN THE U.S. WILL PROVIDE ITS INVESTIGATIONAL PRODUCTS FREE OF CHARGE TO PARTICIPATING HOSPITALS FIRST PATIENTS ARE EXPECTED TO BE TREATED IN SECOND HALF OF 2025 Source text: ID:nMFN7vp4qj Further company coverage: SEDANA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln